International Stem Cell announced the completion of its preclinical studies in Traumatic Brain Injury program will position it to commence a Phase II clinical trial in Australia.
International Stem Cell (OTCQB:ISCO) announced the completion of its preclinical studies in Traumatic Brain Injury program will position it to commence a Phase II clinical trial in Australia.
As quoted in the press release:
“Often referred to as a silent epidemic, TBI represents a significant unmet medical need with millions affected annually. Based on the results of our proprietary ISC-hpNSC® demonstrated in our Parkinson’s disease clinical trial and in the preclinical studies conducted by the world-renowned academic collaborator, we believe ISC-hpNSC® can be an effective therapy for TBI” remarked Andrey Semechkin, PhD., Co-Chairman and CEO of ISCO.
“We are very impressed by the results of our TBI preclinical studies. Both motor and cognitive functions improved with neural stem cells ISC-hpNSC® transplantation without any safety issues,” commented Russell Kern, PhD., Executive Vice President and Chief Scientific Officer of ISCO.